Mirati Therapeutics (MRTX) is Downgraded by Jefferies to Hold

Mirati Therapeutics (MRTX) was Downgraded by Jefferies to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Jefferies advised their investors in a research report released on Jun 6, 2016.

Many Wall Street Analysts have commented on Mirati Therapeutics. Shares were Reiterated by Wedbush on May 24, 2016 to “Outperform” and Lowered the Price Target to $ 29 from a previous price target of $41 .Shares were Reiterated by Wedbush on May 9, 2016 to “Outperform” and Lowered the Price Target to $ 41 from a previous price target of $45 .

Mirati Therapeutics closed down -0.73 points or -3.83% at $18.35 with 1,27,315 shares getting traded on Friday. Post opening the session at $19.01, the shares hit an intraday low of $18.02 and an intraday high of $19.2523 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Jan 19, 2016, Mark J Gergen (Executive VP, COO) sold 10,000 shares at $25.92 per share price. According to the SEC, on May 27, 2015, Jamie Christensen (SVP & Chief Scientific Officer) sold 4,750 shares at $28.07 per share price.

Mirati Therapeutics

Leave a Reply

Mirati Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Mirati Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.